Alembic Pharmaceuticals, a Rs.2,000 crore pharma major from Vadodara, has posted net profit growth of 8.1 per cent during the first quarter ended June 2015 to Rs.69.88 crore as against Rs.64.67 crore in the corresponding period of last year. EBIDTA increased by 6.1 per cent to Rs.102.08 crore from Rs.96.20 crore. Its net sales moved up by 17.9 per cent to Rs.582.41 crore from Rs.493.65 crore. EPS improved to Rs.3.71 from Rs.3.43 in the last period.

Its domestic sales increased by 9 per cent to Rs.303.36 crore from Rs.278.40 crore. The sales of branded formulations improved by 18 per cent to Rs.263 crore from Rs.223 crore and its specialty segment sales grew by 22 per cent. The sales of acute segment moved up by 12 per cent. Its exports went up by 31.8 per cent to Rs.286.98 crore from Rs.217.73 crore. Alembic has launched Aripiprazole generic successfully in international market. Its sales of international generics grew by 47 per cent to Rs.168 crore. It received approvals for 8 ANDAs during the quarter under review. It filed one DMF, taking cumulative DMF filings of the company to 73. US FDA has successfully audited its API Karkhadi plant.

Shaunak Amin, joint managing director, said, “We have seen exceptional growth in the topline on all the businesses, we however have also accelerated our R&D programme, which led to an expense increase of 62 per cent which has impacted our margins.”